Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

Although programmed death-ligand 1 (PD-L1) expression on tumor tissue is a validated predictive biomarker for a PD-1 pathway blockade in non-small cell lung cancer (NSCLC), longitudinal changes in its expression during treatment remains elusive. Circulating tumor cells (CTCs) are assumed to reflect...

Full description

Bibliographic Details
Main Authors: Mio Ikeda, Yasuhiro Koh, Shunsuke Teraoka, Koichi Sato, Jun Oyanagi, Atsushi Hayata, Nahomi Tokudome, Hiroaki Akamatsu, Yuichi Ozawa, Katsuya Endo, Masayuki Higuchi, Masanori Nakanishi, Hiroki Ueda, Nobuyuki Yamamoto
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
liquid biopsy
circulating tumor cells
lung cancer
PD-L1
nivolumab
Online Access:https://www.mdpi.com/2072-6694/13/10/2290

Internet

https://www.mdpi.com/2072-6694/13/10/2290

Similar Items